Evan Seigerman's questions to Schrodinger Inc (SDGR) leadership • Q3 2024
Question
Evan Seigerman of BMO Capital Markets asked about P&L management amid advancing clinical programs and the go/no-go efficacy bar for moving beyond Phase I.
Answer
CFO Geoff Porges addressed P&L management, stating a focus on reducing OpEx growth to achieve operating leverage. He clarified that the company does not plan to advance all portfolio assets on its own. President of R&D Karen Akinsanya added that the efficacy bar for MALT1, CDC7, and Wee1 is evidence of monotherapy activity, which is crucial before exploring combinations.